AI-assisted models to predict chemotherapy drugs modified with C₆₀ fullerene derivatives

• Jonathan-Siu-Loong Robles-Hernández,
• Dora Iliana Medina,
• Katerin Aguirre-Hurtado,
• Marlene Bosquez,
• Roberto Salcedo and
• Alan Miralrio

Beilstein J. Nanotechnol. 2024, 15, 1170–1188, doi:10.3762/bjnano.15.95

• to compare results obtained by DFTB3 with a conventional density functional theory approach. These findings promise to enhance breast cancer chemotherapy by leveraging fullerene-based drug nanocarriers. Keywords: breast cancer; CXCR7; drug nanocarriers; QSAR; Introduction Breast cancer is the most

• described in the subsequent subsection. In case of the complexes with C60, the molecular weight is obtained with values above 907.1639 g/mol. The above imposes some restrictions on the usage of fullerene derivatives as drug nanocarriers, since it is accepted that common pharmacological agents applied in

• commonly used for breast cancer chemotherapy modified with fullerene derivatives as drug nanocarriers was carried out. The CXCR7 protein was selected as a target for molecular docking calculations; the drugs were studied in the isolated form and modified with C60 fullerene and with the water-soluble C60

Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis

• Damai Ria Setyawati,
• Fransiska Christydira Sekaringtyas,
• Riyona Desvy Pratiwi,
• A’liyatur Rosyidah,
• Rohimmahtunnissa Azhar,
• Nunik Gustini,
• Gita Syahputra,
• Idah Rosidah,
• Etik Mardliyati,
• Tarwadi and
• Sjaikhurrizal El Muttaqien

Beilstein J. Nanotechnol. 2024, 15, 1105–1116, doi:10.3762/bjnano.15.89

• treatment. The enhanced permeability and retention (EPR) effect, first described by Maeda and co-workers in 1986, allows for high accumulation of the drug nanocarriers via the leaky vasculature and the deficient lymphatic system around solid tumors, as illustrated in the right panel of Figure 1 [3][4][5

Fluorescent bioinspired albumin/polydopamine nanoparticles and their interactions with Escherichia coli cells

• Eloïse Equy,
• Jordana Hirtzel,
• Sophie Hellé,
• Béatrice Heurtault,
• Eric Mathieu,
• Morgane Rabineau,
• Vincent Ball and
• Lydie Ploux

Beilstein J. Nanotechnol. 2023, 14, 1208–1224, doi:10.3762/bjnano.14.100

• nanoplastics can penetrate and accumulate in bacterial cells [22], thus suggesting that other ONPs may have a similar fate in bacteria. In general, the mechanisms of action of ONPs used as drug nanocarriers in antibacterial applications are expected to vary with the nanoparticle type (e.g., liposomes or PLGA

Comparison of the interactions of daunorubicin in a free form and attached to single-walled carbon nanotubes with model lipid membranes

• Dorota Matyszewska

Beilstein J. Nanotechnol. 2016, 7, 524–532, doi:10.3762/bjnano.7.46

• transport daunorubicin to cancer cells [5]. Drug delivery systems are aimed at providing enhanced transport of therapeutic agents directly to the targeted organs and tissues, which enables the elimination or significant decrease in the side effects of a drug. One of the most common type of drug nanocarriers